US Patent Issued to Amenis Bioscience on July 15 for "Anthranilic acid-based compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same" (Japanese Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,357,626, issued on July 15, was assigned to Amenis Bioscience Inc. (Seoul, South Korea).

"Anthranilic acid-based compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same" was invented by Tomoichiro Asano (Hiroshima, Japan), Yusuke Nakatsu (Hiroshima, Japan), Hisanaka Ito (Hachioji, Japan) and Takayoshi Okabe (Tokyo).

According to the abstract* released by the U.S. Patent & Trademark Office: "The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt ther...